Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Debt Investor Presentation (May 2016)

31 slides from Walgreens Boots Alliance's debt investor presentation, May 9, 2016

  1. Slide 1: Fixed income investor presentation May 2016

    Slide 1: Fixed income investor presentation May 2016

    Fixed income investor presentation May 2016 Exhibit 99.1

  2. Slide 2: Forward-looking statements and offering disclaimer

    Slide 2: Forward-looking statements and offering disclaimer

    Statements in these materials that are not historical are forward-looking statements made based on current market, business and regulatory expectations and involve risks, uncertainties and assumptions that could cause actual results to vary materially. Except to the extent required by the law, we un

  3. Slide 3: Agenda

    Slide 3: Agenda

    Agenda Company highlights 4 WBA segments and brands overview11 Pending Rite Aid acquisition overview19 Q&A23 Appendix24

  4. Slide 4: Company highlights

    Slide 4: Company highlights

    Company highlights 5 " Walgreens Boots Alliance

  5. Slide 5: A market leader with complementary capabilities and assets

    Slide 5: A market leader with complementary capabilities and assets

    Company highlights 10 A market leader with complementary capabilities and assets Significant global size and scale Diversified revenue and profit pools Synergy track record Commitment to solid investment grade rating Strong management team with track record of success

  6. Slide 6: Walgreens Boots Alliance today

    Slide 6: Walgreens Boots Alliance today

    LTM sales to external customers by division Financial highlights A leader in the retail pharmacy industry A leading global pharmaceutical wholesaler and distributor A leading drugstore chain in the USA The first global pharmacy-led, health and wellbeing enterprise in the world Walgreens Boots Allian

  7. Slide 7: Unique global presence

    Slide 7: Unique global presence

    Unique global presence One of the largest global pharmaceutical wholesale and distribution networks with over 3501 distribution centers in 191 countries One of the largest retail pharmacy, health and daily living destinations in the USA and Europe One of the world’s largest purchasers of prescriptio

  8. Slide 8: Large scale and cash flow generation

    Slide 8: Large scale and cash flow generation

    Large scale and cash flow generation Net sales Adjusted operating income2 Leverage as of February 29, 2016 Free cash flow generation2 1 LTM as of February 29, 2016 2 Non GAAP financial measure – see attached Appendix 3 Adjusted by adding rent expense using a multiple of 8. Rent expense based on FY 2

  9. Slide 9: Synergy track record: Walgreens-Alliance Boots transaction

    Slide 9: Synergy track record: Walgreens-Alliance Boots transaction

    Synergy track record: Walgreens-Alliance Boots transaction ($ millions) 1 For FY 2013 only full year realized synergies reported 1

  10. Slide 10: Financial policy and strategy

    Slide 10: Financial policy and strategy

    Financial policy and strategy1 Committed to solid investment grade credit ratings Optimal for an enterprise of our size and scale Important for maintaining significant access to commercial paper Supported by current share repurchase suspension (other than anti-dilutive activity associated with emplo

  11. Slide 11: WBA segments and brands overview

    Slide 11: WBA segments and brands overview

    WBA segments and brands overview

  12. Slide 12: Retail Pharmacy USA segment

    Slide 12: Retail Pharmacy USA segment

    Retail Pharmacy USA segment Two great retail pharmacy brands: Walgreens and Duane Reade 8,1871 drugstores in 501 states, the District of Columbia, Puerto Rico and the US Virgin Islands Approximately 68 million visits per month to Walgreens websites as of August 31, 2015 Approximately 76% of the popu

  13. Slide 13: Building an even better Walgreens

    Slide 13: Building an even better Walgreens

    Building an even better Walgreens1 Enabled by sophisticated, focused IT systems that support these core activities 1 Forward-looking statements – see cautionary note in attached Appendix Recapture our position as America’s most loved pharmacy Focus on dispensing Front of store margin expansion Devel

  14. Slide 14: Pharmacy experience and operations

    Slide 14: Pharmacy experience and operations

    Pharmacy experience and operations Growth in prescription volume1 19.5%2 prescription market share Relationships with payers Patient experience Patient access Medicare Part D growth strategy OptumRx Select 90 Express Scripts Smart 90 Specialty pharmacy Specialty at retail Leveraging our national cen

  15. Slide 15: Front of store margin expansion

    Slide 15: Front of store margin expansion

    Front of store margin expansion Optimizing assortment and space Expanding health and beauty space Format trials Rolling out new beauty experience in 2016 No7, Soap & Glory and Botanics Service model and enhanced enviornment Focused on delivering reliable value Enhanced promotional strategy Omnichann

  16. Slide 16: Retail Pharmacy International segment

    Slide 16: Retail Pharmacy International segment

    Retail Pharmacy International segment Strong market positions in Europe, Latin America and Asia Principal retail brands: Boots in the United Kingdom, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania, Farmacias Ahumada in Chile and Farmacias Benavides in Mexico 4,6031 pharmacy

  17. Slide 17: Pharmaceutical Wholesale segment

    Slide 17: Pharmaceutical Wholesale segment

    Pharmaceutical Wholesale segment A leading pharmaceutical wholesaler in Europe Mainly operating under the Alliance Healthcare brand A network of 3021 distribution centers delivering medicines, other healthcare products and related services to more than 140,0002 pharmacies, doctors, health centers an

  18. Slide 18: Owned product brands

    Slide 18: Owned product brands

    Owned product brands Portfolio of highly regarded and long established product brands, which we continue to internationalize

  19. Slide 19: Pending Rite Aid acquisition overview

    Slide 19: Pending Rite Aid acquisition overview

    Pending Rite Aid acquisition overview

  20. Slide 20: Rite Aid business overview

    Slide 20: Rite Aid business overview

    Rite Aid business overview1 Revenues Retail Pharmacy revenue by product2 Adjusted EBITDA3 ($ millions) ($ millions) Geographical split2 104 139 37 190 22 81 91 72 224 604 1 225 26 275 79 62 116 10 13 179 20 580 93 537 68 146 44 77 257 42 140 MD 7 D.C. Rite Aid States / Store Count Rite Aid Distribut

  21. Slide 21: Acquisition overview

    Slide 21: Acquisition overview

    Acquisition overview Offer price $9.00 per share in cash, total enterprise value of $16.6 billion1 Rite Aid shareholder approval Rite Aid shareholders approved on 4 February 2016 Regulatory approval Subject to regulatory approval and other customary closing conditions Contract provides for divestmen

  22. Slide 22: Strategic rationale

    Slide 22: Strategic rationale

    Strategic rationale Acquisition rationale Complements Walgreens footprint, filling gaps in the Northeast and Southern California Economies of scale create efficiencies and cost savings Provides opportunity to develop the Rite Aid retail product offering Shift to improve category mix Expand distribut

  23. Slide 23: Q&A

    Slide 23: Q&A

    Q&A

  24. Slide 24: Appendix

    Slide 24: Appendix

    Appendix = Walgreens Boots Alliance

  25. Slide 25: Reconciliation of supplemental non-GAAP financial measures

    Slide 25: Reconciliation of supplemental non-GAAP financial measures

    The following information provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles in th

  26. Slide 26: Reconciliation of non-GAAP financial measures: free cash flow

    Slide 26: Reconciliation of non-GAAP financial measures: free cash flow

    Reconciliation of non-GAAP financial measures Note: LTM as of February 29, 2016 1 Free cash flow is defined as net cash provided by operating activities in a period minus additions to property, plant and equipment (capital expenditures) made in that period. This measure does not represent residual c

  27. Slide 27: Adjusted Operating Income, EBITDA and Adjusted Debt

    Slide 27: Adjusted Operating Income, EBITDA and Adjusted Debt

    Walgreens Boots Alliance, Inc. and Subsidiaries FY 2014 FY 2015 2H FY 2015 1H FY 2016 2016 LTM Adjusted Operating Income, EBITDA and Adjusted Debt 12M ending Aug 31 12M ending Aug 31 6M ending Aug 31 6M ending Feb 29 12M ending Feb 29 (In millions) Operating Income (GAAP) $ 4,194 $ 4,668 $ 2,237 $ 3

  28. Slide 28: Adjusted Net Earnings reconciliation

    Slide 28: Adjusted Net Earnings reconciliation

    Note: LTM as of February 29, 2016 1 Net investment hedge gains/losses are reported as an adjustment prospectively beginning in FY15 4Q. Net investment hedge gains of $10 million or $0.01 per share in FY15 2Q and $7 million or $0.01 per share in FY15 3Q were included in the company’s GAAP and adjuste

  29. Slide 29: Adjusted Net Earnings per Share reconciliation

    Slide 29: Adjusted Net Earnings per Share reconciliation

    Note: LTM as of February 29, 2016 1 Net investment hedge gains/losses are reported as an adjustment prospectively beginning in FY15 4Q. Net investment hedge gains of $10 million or $0.01 per share in FY15 2Q and $7 million or $0.01 per share in FY15 3Q were included in the company’s GAAP and adjuste

  30. Slide 30: Rite Aid reconciliation of non-GAAP financial measures

    Slide 30: Rite Aid reconciliation of non-GAAP financial measures

    Rite Aid - Reconciliation of non-GAAP financial measures Note: Data presented for Rite Aid 52 week periods ending March 1, 2014, February 28, 2015 and February 27,2016. Based on reconciliation provided in Rite Aid Annual Report on Form 10-K for the 52 week period ending February 27, 2016, filed with

  31. Slide 31: Cautionary note regarding forward-looking statements

    Slide 31: Cautionary note regarding forward-looking statements

    This Presentation includes “forward‐looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on current expectations, estimates, forecasts and projections about Walgreens Boots A

Source: SEC EDGAR · 8-K filed May 9, 2016

More decks from Walgreens Boots Alliance Inc